Security record · archived quarter
ERAS
Erasca, Inc. · Healthcare · Biotechnology
11Tracked holders
—Δ holders
15.91MShares held
$37.56MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +13 | 109.93M | $2.01B | +17 | −4 |
| Q1 2026 | 87 | +18 | 99.27M | $1.57B | +25 | −7 |
| Q4 2025 | 69 | +1 | 63.96M | $237.91M | +1 | — |
| Q3 2025 | 16 | +1 | 49.01M | $106.84M | +1 | — |
| Q2 2025 | 12 | -3 | 45.80M | $58.17M | — | −3 |
| Q1 2025 | 12 | 0 | 17.13M | $23.47M | +1 | −1 |
| Q4 2024 | 12 | 0 | 25.73M | $64.58M | +1 | −1 |
| Q3 2024 | 11 | 0 | 18.60M | $50.78M | — | — |
| Q2 2024 | 11 | — | 15.91M | $37.56M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 3.67M | — | $8.67M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Marshall Wace ✦ | 3.67M | — | $8.67M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.31M | — | $7.82M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.31M | — | $7.82M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 3.29M | — | $7.77M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 1.58M | — | $3.72M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 1.04M | — | $2.44M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 1.00M | — | $2.36M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 814.77K | — | $1.92M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 804.48K | — | $1.90M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 315.55K | — | $744,705 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 55.72K | — | $131,504 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 55.72K | — | $131,504 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 55.72K | — | $131,504 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 36.15K | — | $86,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 223 holders, 272.55M shares, $4.00B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API